Revela is now ODDITY LABS. Read the press release.
Our Mission

A Game-Changer For
Thinning Hair. Aging Skin. Nutrition. Total Wellness.

Innovation has been stagnant in beauty and wellness for decades.
Across hair, skin, and body wellness, genuine innovation and discovery has been avoided in favor of less challenging programs to retest and reformulate legacy ingredients.

MOLECULAR DISCOVERY

REVELA IS A SCALABLE MOLECULAR DISCOVERY PLATFORM

We leverage our molecular discovery pipeline to drive molecule and biological modality development for the most pressing visible (and invisible) challenges of wellness.

Rendered image of cells
MACHINE LEARNING & BIOENGINEERING

RAISING THE BAR FOR EXPECTATIONS IN CONSUMER HEALTH & WELLNESS

To achieve our mission, we use the same cutting-edge bioengineering and advanced AI techniques used to develop new medicines and cancer therapeutics and apply them to discover new molecules that directly target the issues impacting millions of people every day.

Revela scientist pipetting in laboratory
Product Development

Never settle for good enough. We don't.

It's 2024. We have supercomputers in our pockets and technologies to edit entire genomes, yet consumers are still forced to accept the same ingredients their grandparents had, and continue to experience the same underwhelming results.

The products using our breakthrough molecules demonstrate safe and superior clinical efficacy as compared to what's currently on the market. Rather than rebranding what is already available, we reinvent what just isn't cutting it for consumers.

CLARITY image of tissues, staining for macrophages and vessels
200+

Molecules Patent Pending

> 1B

Screenable Molecules

> 25K

Molecules Screened / Second

PIPELINE

BRIDGING MOLECULE DISCOVERY AND BEAUTY & WELLNESS

We explore the universe of existing and potential molecules with our multi-layered technology platform

Schematic of pipeline
Schematic of Revela data generation

Data Generation

Robotic Phenotypic Screening
Medicinal Chemistry
Omic Sequencing
Schematic of Revela AI & scientific compute

AI & Scientific Compute

In silico Molecular Screening
Deep Learning
Computational Biology
Schematic of Revela molecular validation

Molecular Validation

Assay development
In vitro validation
Product development & formulation
Schematic of Revela exvivo testing

Ex Vivo & In Vivo Testing

Advanced biological models
Ex vivo testing
Clinical testing
Developing biological models

Develop Biological Models

Advanced Biological Models
Assay Development
Synthetic Biology
Generating data

Generate Data

Robotic High-Throughput Screening
'Omic Sequencing
Medicinal Chemistry
AI molecule screening and optimization

AI Molecule Screening & Optimization

In silico Molecular Screening
Deep Learning
Computational Biology
Lead validation and safety testing

Lead Validation & Safety Testing

In vitro Efficacy Validation
Safety & Toxicity Screening
Ex vivo & Clinical Testing
Product development

Product Development

Analytical Chemistry
Formulation
Evan Zhao
Evan Zhao, PhD
Chief Scientific Officer
Former Schmidt Science Fellow. Synthetic biologist and chemical engineer. Evan received his B.S. in Chemical Engineering from Caltech and Ph.D. in Chemical Engineering from Princeton where he pioneered the use of optogenetics in metabolic engineering and protein therapeutics. Evan is the lead author of numerous high-impact publications in Nature, Nature Biotechnology, Nature Chemical Biology, Nature Communications, and more.
David K.Y. Zhang
David Zhang, PhD
Head of Bioengineering
Immunologist and bioengineer. David Received his B.S. from McGill University, M.A.Sc from the University of Toronto, and Ph.D from Harvard University, where he developed next-generation cancer therapy technologies. He is an author or inventor on several high profile publications and patents, and has licensed his technologies to a clinical-stage biopharma company.
Avinash Boppana
Avinash Boppana
Head of Platform
Computer scientist and expert in computational methods for molecule discovery and systems biology. Avi received his B.S.E from Princeton University where he created novel algorithms for genomics-informed therapeutic development. He has published in top journals including Nature Cell Biology, and has previous experience at Harvard Medical School and the NIH.
Connor Coley MIT professor
Connor Coley, PhD
Scientific Advisor
Henri Slezynger (1957) Career Development Assistant Professor at Massachusetts Institute of Technology and Forbes' 30 Under 30. Connor is a renowned expert in computational chemical engineering, where he and his group develop methods at the frontier of computer-aided chemical discovery and synthesis. He was awarded the NSF Career Award and is also a Schmidt AI2050 Early Career Fellow.
Enzo Benfanti
Enzo Benfanti
Head of New Molecule Operations
Product manager and chemical engineer. Enzo received his B.S. in Chemical Engineering from the University at Buffalo and his M.Eng in Chemical Engineering from Columbia University. He brings with him extensive experience in process chemistry and product development.
TEAM

A CROSS-DISCIPLINARY TEAM OF ENGINEERS, BIOLOGISTS, AND COMPUTER SCIENTISTS

Our team have backgrounds in synthetic biology, cancer therapeutics, tissue engineering, chemo-genomics, small-molecule synthesis and discovery. Are you a passionate scientist looking for something different? Let us know!
Open positions
Evan Zhao
Evan Zhao, Phd
Chief Science Officer
Former CEO of Revela. Former Schmidt Science Fellow. Synthetic biologist and chemical engineer.
David K.Y. Zhang
David ZHANG, Phd
Head of Bioengineering
Former CSO of Revela. Immunologist and bioengineer.
Avinash Boppana
Avi Boppana
Head of Platform
Former CTO of Revela. Computer scientist and expert in computational methods for molecule discovery.
Enzo Benfanti
Enzo Benfanti, MEng
Head of New Molecule Ops
Former Director of Operations at Revela. Chemical engineer and product manager.
Connor Coley MIT professor
Connor Coley, PhD
Scientific advisor
Henri Slezynger (1957) Career Development Assistant Professor at Massachusetts Institute of Technology and Forbes' 30 Under 30.
Wess Zhang, MS
Research Associate
Michelle Sucre, MS
Formulation Chemist
Makoto Lalwani, PhD
Scientist, Bioengineering
Hector E. Acaron, PhD
Scientist, Bioengineering
Faraz Shaikh, PhD
Scientist, Computational Chemistry
Anjali Gupta, PhD
Scientist, Molecular Biology
Mia DyBuncio
Manager, Product Development
Zeta Doufexi, MS
Research Associate
Jingyun Yang, PhD
Scientist, Bioengineering
Apurba Bhattarai, PhD
Scientist, Computational Chemistry
Fernanda Pace, PhD
Scientist, Stem Cell Biology
Press
ODDITY Invests $100M to Bring Pharma’s AI Based Molecule Discovery Technology to Beauty and Wellness.
“With the acquisition of Boston-based Revela, a leading biotech startup, and the establishment of ODDITY LABS, the company is at the vanguard, bringing a proven drug discovery technology into beauty and wellness.”

Continue reading.
ODDITY LABS
Why the "Biotech" Boom Has Potential to Spur Real Change in the Beauty Industry
Beauty consumers are constantly searching for products that deliver on their marketing promises. But for all the advances beauty innovation is capable of from a formulation perspective, there are some limits to what is possible by cosmetic chemists in a lab.

Keep reading.
Byrdie magazine
Why the "Biotech" Boom Has Potential to Spur Real Change in the Beauty Industry
Beauty consumers are constantly searching for products that deliver on their marketing promises. But for all the advances beauty innovation is capable of from a formulation perspective, there are some limits to what is possible by cosmetic chemists in a lab.

Keep reading.
Byrdie magazine
Intel Ignite Selects 10 Leading-Edge Companies for First Startup Growth Program in the US
"Each of the startups selected for the Boston cohort is unique and disruptive. From quantum to AI to nano, these startups are building and innovating for the future, and they are pushing the envelope of what it means to create impact in deep tech."

Keep reading.
Intel Ignite
Meet the AI-Discovered Skin-Care Ingredient, Fibroquin
Who would even know where to begin finding the next "notable contender" in the antiaging skin-care space? In the case of the latest ingredient, Fibroquin, it turns out that the answer is downright robotic (wink, wink)

Continue reading.
Popsugar magazine

CuRIOUS ABOUT ODDITY?